Key Points
- President Amir Heshmatpour purchased 10,000 shares on April 23 at $4.90 each for $49,000, raising his holdings to 3,052,000 shares (about $14.95M), a 0.33% increase in his position.
- The stock opened at $4.79 and is trading well below its 50‑ and 200‑day moving averages ($7.69 and $8.73), with a 1‑year range of $3.20–$12.99, while analyst coverage is limited and averages a "Reduce" rating (one Hold, one Sell).
- Neonc Technologies focuses on CNS therapeutics, notably NEO100 (in Phase 2a for glioblastoma) and NEO212 (preclinical), after incorporating in 2023.
Neonc Technologies Holdings, Inc. (NASDAQ:NTHI - Get Free Report) President Amir Heshmatpour bought 10,000 shares of the firm's stock in a transaction that occurred on Thursday, April 23rd. The stock was bought at an average price of $4.90 per share, with a total value of $49,000.00. Following the completion of the acquisition, the president owned 3,052,000 shares of the company's stock, valued at $14,954,800. This trade represents a 0.33% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Neonc Technologies Stock Performance
Shares of NASDAQ NTHI opened at $4.79 on Friday. The stock's 50-day moving average is $7.69 and its two-hundred day moving average is $8.73. Neonc Technologies Holdings, Inc. has a 1-year low of $3.20 and a 1-year high of $12.99.
Analysts Set New Price Targets
A number of analysts recently weighed in on NTHI shares. Weiss Ratings restated a "sell (e+)" rating on shares of Neonc Technologies in a research note on Friday, March 27th. Zacks Research raised shares of Neonc Technologies to a "hold" rating in a report on Wednesday, January 14th. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Reduce".
Check Out Our Latest Analysis on Neonc Technologies
Institutional Trading of Neonc Technologies
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. HighPoint Advisor Group LLC increased its holdings in shares of Neonc Technologies by 20.5% in the 4th quarter. HighPoint Advisor Group LLC now owns 1,144,640 shares of the company's stock valued at $9,466,000 after acquiring an additional 194,408 shares during the last quarter. Bank of America Corp DE lifted its stake in Neonc Technologies by 1.0% during the third quarter. Bank of America Corp DE now owns 226,486 shares of the company's stock worth $2,056,000 after purchasing an additional 2,207 shares during the last quarter. Vanguard Group Inc. acquired a new position in Neonc Technologies in the third quarter valued at approximately $1,279,000. 683 Capital Management LLC acquired a new position in Neonc Technologies in the fourth quarter valued at approximately $442,000. Finally, Global Retirement Partners LLC purchased a new position in Neonc Technologies in the third quarter valued at approximately $434,000.
About Neonc Technologies
(
Get Free Report)
Neonc Technologies Holdings, Inc develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
